Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Harvard Business School
Medtronic
Moodys
Merck
Baxter
AstraZeneca

Last Updated: May 28, 2022

CLINICAL TRIALS PROFILE FOR DACTINOMYCIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Dactinomycin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002489 ↗ Combination Chemotherapy in Treating Children With Non-testicular Malignant Germ Cell Tumors Completed Memorial Sloan Kettering Cancer Center Phase 2 1991-10-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have non-testicular malignant germ cell tumors.
NCT00002516 ↗ Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status Medical Research Council Phase 3 1992-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with surgery and radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with Ewing's sarcoma. PURPOSE: Randomized phase III trial to compare various combination chemotherapy regimens plus surgery and radiation therapy in treating patients who have Ewing's sarcoma.
NCT00002516 ↗ Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status University Hospital Muenster Phase 3 1992-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining more than one drug with surgery and radiation therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating patients with Ewing's sarcoma. PURPOSE: Randomized phase III trial to compare various combination chemotherapy regimens plus surgery and radiation therapy in treating patients who have Ewing's sarcoma.
NCT00002610 ↗ Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed National Cancer Institute (NCI) Phase 3 1996-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
NCT00002610 ↗ Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed Children's Oncology Group Phase 3 1996-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
NCT00002611 ↗ Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed National Cancer Institute (NCI) Phase 3 1995-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.
NCT00002611 ↗ Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer Completed Children's Oncology Group Phase 3 1995-07-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. It is not yet known whether combination chemotherapy alone or combination chemotherapy plus radiation therapy is more effective for childhood kidney cancer. PURPOSE: Phase III trial to compare the effectiveness of combination chemotherapy with or without radiation therapy in treating children who have kidney cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Dactinomycin

Condition Name

Condition Name for Dactinomycin
Intervention Trials
Sarcoma 13
Kidney Cancer 5
Adult Rhabdomyosarcoma 4
Rhabdomyosarcoma 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Dactinomycin
Intervention Trials
Rhabdomyosarcoma 17
Sarcoma 16
Wilms Tumor 10
Rhabdomyosarcoma, Embryonal 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Dactinomycin

Trials by Country

Trials by Country for Dactinomycin
Location Trials
United States 763
Canada 122
Australia 66
Japan 49
New Zealand 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Dactinomycin
Location Trials
New York 22
Texas 21
California 21
Pennsylvania 20
Ohio 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Dactinomycin

Clinical Trial Phase

Clinical Trial Phase for Dactinomycin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 26
Phase 2 15
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Dactinomycin
Clinical Trial Phase Trials
Completed 18
Unknown status 11
Active, not recruiting 6
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Dactinomycin

Sponsor Name

Sponsor Name for Dactinomycin
Sponsor Trials
National Cancer Institute (NCI) 24
Children's Oncology Group 16
Children's Cancer and Leukaemia Group 5
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Dactinomycin
Sponsor Trials
Other 64
NIH 24
Industry 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Express Scripts
Mallinckrodt
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.